Buy or sell Tessera Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Tessera Therapeutics Stock

Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.

Founded

2018

Notable Investors

Flagship Pioneering

Headquarters

Cambridge MA, US

Total Funding

$533M

About Tessera Therapeutics Stock

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Investors

Funding History

May 2020$2.7M
January 2021$230M
April 2022$300M

Management

Co-Founder & Chief Scientific Officer

Jacob Rubens

President and CFO

Howard Liang

Chief Data Officer

Iain McFadyen

Co-Founder, Chief Executive Officer & Board member

Geoffrey von Maltzahn

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo